Clinical Trials Directory

Trials / Unknown

UnknownNCT00435799

Evaluating Collagen Cross-Linking (CCL) Treatment in Norway

Treatment of Keratectasia With Collagen Cross-Linking (CCL) at the Eye Departments of the University Hospital, North Norway in Tromsø and Ullevål University Hospital in Oslo

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Ullevaal University Hospital · Academic / Other
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.

Detailed description

The technique of corneal collagen cross-linking consists of photopolymerization of stromal fibers by combined action of a photosensitizing substance, riboflavin and ultraviolet type A rays (UVA) from a solid-state UVA Source. Photopolymerization increases the rigidity of corneal collagen and its resistance to keratectasia. It has been used to stop progression of keratectasia. Corneal transplantation has been the only available option so far for treatment for keratectasia in its advanced stage in Norway. The method of CCL using riboflavin and UV light is technically simple and much less invasive than corneal transplantation and it treats and prevents the underlying pathophysiological mechanism. It also does not reduce the chances for a successful corneal transplantation, in case that would still be necessary after CCL. The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.

Conditions

Interventions

TypeNameDescription
PROCEDUREcorneal cross-linking (CCL)
DRUGRiboflavin/dextran eyedrops
DEVICEUV-X system

Timeline

Start date
2007-02-01
Primary completion
2009-01-01
Completion
2010-01-01
First posted
2007-02-15
Last updated
2008-06-10

Locations

2 sites across 1 country: Norway

Source: ClinicalTrials.gov record NCT00435799. Inclusion in this directory is not an endorsement.